Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein LEG1 homolog (LEG1)
- Target
- LEG1
- Molecular classification
- Other (Secreted protein with Domain of Unknown Function 781 [DUF781]; not an established member of major target families such as receptor, enzyme, ion channel, or transporter)
01
Overview
Protein LEG1 homolog (LEG1, encoded by C6orf58) is a poorly characterized, secreted glycoprotein defined by the presence of the Domain of Unknown Function 781 (DUF781, also called LEG1 domain)[1][3]. First identified as liver-enriched in zebrafish, where it participates in liver development, its role in mammals and humans remains unclear[1][3]. In non-human species, related proteins have been implicated in processes including liver development, endoplasmic reticulum stress response, and antibacterial activity (platypus)[1][3]. In humans, only one ortholog (LEG1a) exists, and there are no comprehensive functional studies or disease associations to date[1][3][5]. Protein LEG1 homolog is not recognized as a receptor, enzyme, transporter, or other well-studied drug target, nor is it currently targeted by any medications or biologics in clinical use[1][3][5].
- Other names
- Chromosome 6 open reading frame 58C6orf58Liver enriched gene 1 homologLEG1UPF0762 protein C6orf58
02
Mechanism of action
Not applicable; no drugs target this protein.
03
Biological functions
Potential role in *multicellular organism development* (predicted by bioinformatic tools)Possible involvement in *liver development* (from zebrafish studies; unclear in humans)Possible function in ER stress response, protein folding, translation or transcriptional regulation (only suggested in non-human models)Secreted glycosylated protein, presence in saliva, milk, seminal plasmaNo robust, experimentally validated function in humans to date
04
Disease associations
No direct, confirmed association with major human diseases; Patellofemoral Pain Syndrome has been mentioned but is not established as causal or mechanisticPossible generic or developmental relevance, based on animal and in silico studies
05
Safety considerations
Not applicable; there are no therapies targeting LEG1 and no clinical safety data.
06
Interacting drugs
None known or reported. No established small molecule or biologic targeting LEG1 in humans.
07
Biomarkers
None established. No validated use of LEG1 as a biomarker in patient selection or monitoring.
Beyond the preview
Go deeper on Protein LEG1 homolog (LEG1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protein LEG1 homolog (LEG1).